|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCTN4 |
Gene summary for DCTN4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCTN4 | Gene ID | 51164 |
| Gene name | dynactin subunit 4 | |
| Gene Alias | DYN4 | |
| Cytomap | 5q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0000775 | UniProtAcc | Q9NSJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51164 | DCTN4 | P49T-E | Human | Esophagus | ESCC | 2.43e-09 | 1.15e+00 | 0.1768 |
| 51164 | DCTN4 | P52T-E | Human | Esophagus | ESCC | 3.03e-19 | 4.09e-01 | 0.1555 |
| 51164 | DCTN4 | P54T-E | Human | Esophagus | ESCC | 5.35e-26 | 4.65e-01 | 0.0975 |
| 51164 | DCTN4 | P56T-E | Human | Esophagus | ESCC | 4.93e-06 | 1.10e+00 | 0.1613 |
| 51164 | DCTN4 | P57T-E | Human | Esophagus | ESCC | 5.14e-19 | 3.08e-01 | 0.0926 |
| 51164 | DCTN4 | P61T-E | Human | Esophagus | ESCC | 1.84e-17 | 2.53e-01 | 0.099 |
| 51164 | DCTN4 | P62T-E | Human | Esophagus | ESCC | 9.22e-63 | 1.06e+00 | 0.1302 |
| 51164 | DCTN4 | P65T-E | Human | Esophagus | ESCC | 1.05e-18 | 2.06e-01 | 0.0978 |
| 51164 | DCTN4 | P74T-E | Human | Esophagus | ESCC | 1.73e-16 | 4.40e-01 | 0.1479 |
| 51164 | DCTN4 | P75T-E | Human | Esophagus | ESCC | 2.17e-37 | 4.19e-01 | 0.1125 |
| 51164 | DCTN4 | P76T-E | Human | Esophagus | ESCC | 4.21e-23 | 1.45e-01 | 0.1207 |
| 51164 | DCTN4 | P79T-E | Human | Esophagus | ESCC | 4.23e-17 | 1.70e-01 | 0.1154 |
| 51164 | DCTN4 | P80T-E | Human | Esophagus | ESCC | 1.13e-31 | 8.88e-01 | 0.155 |
| 51164 | DCTN4 | P82T-E | Human | Esophagus | ESCC | 5.22e-06 | 4.83e-01 | 0.1072 |
| 51164 | DCTN4 | P83T-E | Human | Esophagus | ESCC | 7.19e-19 | 6.26e-01 | 0.1738 |
| 51164 | DCTN4 | P84T-E | Human | Esophagus | ESCC | 6.89e-03 | 2.07e-01 | 0.0933 |
| 51164 | DCTN4 | P89T-E | Human | Esophagus | ESCC | 5.05e-06 | 5.52e-01 | 0.1752 |
| 51164 | DCTN4 | P91T-E | Human | Esophagus | ESCC | 7.72e-07 | 1.13e+00 | 0.1828 |
| 51164 | DCTN4 | P107T-E | Human | Esophagus | ESCC | 7.99e-19 | 4.92e-01 | 0.171 |
| 51164 | DCTN4 | P126T-E | Human | Esophagus | ESCC | 2.74e-03 | 5.16e-01 | 0.1125 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501630 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| hsa0501430 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
| hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
| hsa0513239 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
| hsa049627 | Esophagus | HGIN | Vasopressin-regulated water reabsorption | 14/1383 | 44/8465 | 8.21e-03 | 4.71e-02 | 3.74e-02 | 14 |
| hsa05016113 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| hsa05014113 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
| hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
| hsa05132115 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
| hsa0496214 | Esophagus | HGIN | Vasopressin-regulated water reabsorption | 14/1383 | 44/8465 | 8.21e-03 | 4.71e-02 | 3.74e-02 | 14 |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0496223 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0496233 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCTN4 | SNV | Missense_Mutation | c.665N>C | p.Lys222Thr | p.K222T | Q9UJW0 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| DCTN4 | SNV | Missense_Mutation | c.201G>C | p.Lys67Asn | p.K67N | Q9UJW0 | protein_coding | deleterious(0) | benign(0.31) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DCTN4 | SNV | Missense_Mutation | c.262N>T | p.Thr88Ser | p.T88S | Q9UJW0 | protein_coding | tolerated(0.18) | possibly_damaging(0.71) | TCGA-BH-A202-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| DCTN4 | SNV | Missense_Mutation | c.1189N>C | p.Asp397His | p.D397H | Q9UJW0 | protein_coding | tolerated(0.06) | possibly_damaging(0.838) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DCTN4 | SNV | Missense_Mutation | novel | c.1285N>G | p.Lys429Glu | p.K429E | Q9UJW0 | protein_coding | tolerated(0.11) | benign(0.117) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DCTN4 | SNV | Missense_Mutation | c.847C>T | p.Arg283Cys | p.R283C | Q9UJW0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DCTN4 | SNV | Missense_Mutation | novel | c.491N>A | p.Arg164His | p.R164H | Q9UJW0 | protein_coding | tolerated(0.12) | benign(0.165) | TCGA-DS-A7WF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| DCTN4 | SNV | Missense_Mutation | c.847N>T | p.Arg283Cys | p.R283C | Q9UJW0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| DCTN4 | SNV | Missense_Mutation | c.35A>T | p.Tyr12Phe | p.Y12F | Q9UJW0 | protein_coding | deleterious(0.04) | possibly_damaging(0.647) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DCTN4 | SNV | Missense_Mutation | novel | c.973N>T | p.Arg325Cys | p.R325C | Q9UJW0 | protein_coding | tolerated(0.12) | possibly_damaging(0.764) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |